Psychological side effects of immune therapies: symptoms and pathomechanism (Q26741695)

Europe PubMed Central

title

Psychological side effects of immune therapies: symptoms and pathomechanism (English)

0 references

1 reference

4

Xenia Gonda

0 references

author name string

David Kovacs

1

0 references

Peter Kovacs

2

0 references

Nora Eszlari

3

0 references

Gabriella Juhasz

Current Opinion in Pharmacology

5

0 references

language of work or name

English

0 references

publication date

August 2016

0 references

published in

1 reference

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

PubMed

volume

29

0 references

page(s)

97-103

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Elevated inflammation levels in depressed adults with a history of childhood maltreatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Interleukin-6 promoter polymorphism interacts with pain and life stress influencing depression phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Psychological changes in melanoma patients during ipilimumab treatment compared to low-dose interferon alpha therapy-a follow-up study of first experiences.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Acute stress effects on local Il-1beta responses to pathogens in a human in vivo model

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Effects of IL1B single nucleotide polymorphisms on depressive and anxiety symptoms are determined by severity and type of life stress.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Subtypes of depressive symptoms and inflammatory biomarkers: An exploratory study on a sample of HIV-positive patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Anterior cingulate activation and error processing during interferon-alpha treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

PD-1/PD-L1 inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Interferons: Success in anti-viral immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Cytokines sing the blues: inflammation and the pathogenesis of depression

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals?

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Social support decreases depressogenic effect of low-dose interferon alpha treatment in melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Neural pathways link social support to attenuated neuroendocrine stress responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Immunomodulatory effects of fluoxetine: A new potential pharmacological action for a classic antidepressant drug?

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Trait sensitivity to social disconnection enhances pro-inflammatory responses to a randomized controlled trial of endotoxin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D).

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Type I interferon signaling genes in recurrent major depression: increased expression detected by whole-blood RNA sequencing

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Neuronal nitric oxide synthase (NOS1) polymorphisms interact with financial hardship to affect depression risk

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Sex differences in depressive and socioemotional responses to an inflammatory challenge: implications for sex differences in depression

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Kynurenines in the CNS: recent advances and new questions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

The role of inflammation in depression: from evolutionary imperative to modern treatment target

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

The interferons: 50 years after their discovery, there is much more to learn

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Immunotherapy for melanoma: current status and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Symptomatic treatment of interferon-α-induced depression in hepatitis C: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

The buffering effect of social support on hypothalamic-pituitary-adrenal axis function during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Nonclassical patrolling monocyte function in the vasculature

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Psychiatric clearance for patients started on interferon-alpha-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Immune Checkpoint Blockade in Cancer Therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Variability in the effect of 5-HTTLPR on depression in a large European population: the role of age, symptom profile, type and intensity of life stressors

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Risk factors for the development of depression in patients with hepatitis C taking interferon-α.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Is There a Role for Adjuvant High-Dose Interferon-??-2b in the Management of Melanoma?

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Neuropsychiatric adverse effects of interferon-alpha: recognition and management

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021

Inflammation and neuronal plasticity: a link between childhood trauma and depression pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COPH.2016.06.008

7 January 2021